Description
3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities.
Product information
CAS Number: 1113-59-3
Molecular Weight: 166.96
Formula: C3H3BrO3
Synonym:
Bromopyruvic acid
Hexokinase II Inhibitor II
3-BP
Chemical Name: 3-bromo-2-oxopropanoic acid
Smiles: OC(=O)C(=O)CBr
InChiKey: PRRZDZJYSJLDBS-UHFFFAOYSA-N
InChi: InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: H2O : ≥ 32 mg/mL (191.66 mM)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
3-Bromopyruvate enhances TRAIL-induced apoptosis in breast cancer cells. 3-Bromopyruvate (Bromopyruvic acid), a hexokinase II inhibitor, can induce apoptosis in hepatocellular carcinoma cells by inducing endoplasmic reticulum (ER) stress. 3-Bromopyruvate inhibits ATP generation and upregulates the expression of DR5. 3-Bromopyruvate upregulates CHOP, GRP78 and the phosphorylation of AMPK and augments TRAIL-induced Bax and caspase-3 levels.
In Vivo:
3-Bromopyruvate (8 mg/kg; i.p.; every 4 days for 28 days) shows a synergistic antitumor effect in MCF-7 cell xenografts in nude mice.
References:
- Gan L, et al. Synergistic Effect of 3-Bromopyruvate in Combination with Rapamycin Impacted Neuroblastoma Metabolism by Inhibiting Autophagy. Onco Targets Ther. 2020;13:11125-11137. Published 2020 Oct 29.
- Chen Y, et al. 3 Bromopyruvate sensitizes human breast cancer cells to TRAIL induced apoptosis via the phosphorylated AMPK mediated upregulation of DR5. Oncol Rep. 2018;40(5):2435-2444.
- Zhang Q, et al. Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer. 2014;5(3-4):100-112.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.